A股盘前市场要闻速递（2026-01-08）

Group 1: Central Bank and Economic Policies - The People's Bank of China has increased its gold reserves for the 14th consecutive month, reaching 74.15 million ounces (approximately 2306.323 tons), with a month-on-month increase of 30,000 ounces (about 0.93 tons) [1] - The Ministry of Industry and Information Technology and eight other departments have issued an implementation opinion to promote the development of intelligent chips, focusing on key technologies such as high-end training chips and AI servers [1] - Multiple departments held a meeting to discuss the battery industry, aiming to regulate competition and promote high-quality development in the lithium battery sector [1] Group 2: Pharmaceutical and Regulatory Updates - The National Medical Products Administration has optimized the review and approval process for urgently needed overseas drugs to meet clinical demands, encouraging simultaneous R&D and application in China [2] - The Ministry of Commerce has initiated an anti-dumping investigation into imported dichlorodihydrosilane from Japan, with the investigation period set from July 1, 2024, to June 30, 2025 [2] Group 3: Company-Specific Developments - Guanglian Aviation plans to acquire a stake in Tianjin Yuefeng to engage in the R&D and manufacturing of core components for commercial rockets, with significant revenue contributions from national tasks [3] - Shenzhen Yihong Technology has received a regulatory warning from the Shanghai Stock Exchange for misleading disclosures regarding its strategic cooperation with Brain Machine Starlink Technology [4] - Shenzhen Yingjixin Technology has also received a regulatory warning for inaccurate disclosures about its brain-computer interface chip, which is still in the market cultivation phase [6] - Fenglong Co. has announced that it may apply for a trading suspension if its stock price continues to rise abnormally, following a significant increase in its stock price over recent trading days [7] - Chengdi Xiangjiang has reported a projected revenue decrease of approximately 1.092 billion yuan due to changes in the investment conditions of a data center project [7] - Zhenxin Technology's subsidiary has been banned from participating in procurement activities in the Western Theater for three years due to collusion in bidding [9] - Koushijiao has projected a 50%-60% decrease in net profit for 2025, primarily due to a significant drop in sales of high-end products [10] - Heng Rui Medicine has received approval for its innovative drug, which is the first of its kind to be approved for market use [11] - Nanjing Panda has clarified that it currently has no mature products related to brain-computer interfaces and has not generated related sales revenue [11] - Guangqi Technology has signed contracts worth a total of 264 million yuan for the mass production of metamaterials [11] - Zhongke Lanyun expects a net profit increase of 367%-377% for 2025, driven by significant gains from investments in other companies [12] - Pulit has developed LCP film technology for brain-computer interfaces and is collaborating with overseas clients for product development [13]